KN046-话题@MedSci

#KN046#

2篇内容 | 1216人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2257292, encodeId=f615225e292ca, content=<a href='/topic/show?id=0e5310542d9' target=_blank style='color:#2F92EE;'>#KN046#</a> <a href='/topic/show?id=7c7f12368262' target=_blank style='color:#2F92EE;'>#KN026#</a> <a href='/topic/show?id=b867125352a8' target=_blank style='color:#2F92EE;'>#HER2阳性非乳腺癌#</a>, objectTitle=STTT | KN026联合KN046在HER2阳性非乳腺癌中的疗效和安全性分析：一项Ib期和II期的综合分析, objectType=article, longId=868330, objectId=171d86833057, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250321/1742563292702_6145188.png, objectUrl=/article/show_article.do?id=171d86833057, replyNumber=0, likeNumber=10, createdTime=2025-03-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=171d86833057, moduleTitle=STTT | KN026联合KN046在HER2阳性非乳腺癌中的疗效和安全性分析：一项Ib期和II期的综合分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=171d86833057)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2186208, encodeId=258221862089b, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a> <a href='/topic/show?id=2916e177389' target=_blank style='color:#2F92EE;'>#白蛋白结合型紫杉醇#</a> <a href='/topic/show?id=0e5310542d9' target=_blank style='color:#2F92EE;'>#KN046#</a>, objectTitle=Nat. Commun：抗PD-L1/CTLA-4双特异性抗体KN046联合白蛋白结合型紫杉醇一线治疗转移性三阴性乳腺癌：多中心II期试验, objectType=article, longId=812453, objectId=d158812453bf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240205/1707138204572_6145188.png, objectUrl=/article/show_article.do?id=d158812453bf, replyNumber=0, likeNumber=121, createdTime=2024-02-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d158812453bf, moduleTitle=Nat. Commun：抗PD-L1/CTLA-4双特异性抗体KN046联合白蛋白结合型紫杉醇一线治疗转移性三阴性乳腺癌：多中心II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d158812453bf)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2040434, encodeId=10d12040434e2, content=<a href='/topic/show?id=0e5310542d9' target=_blank style='color:#2F92EE;'>#KN046#</a>, objectTitle=康宁杰瑞与应世生物宣布合作开展，KN046联合IN10018的临床研究, objectType=article, longId=194632, objectId=2889194632a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2889194632a8, replyNumber=0, likeNumber=80, createdTime=2021-03-01, rootId=0, userName=yilong5287542, userId=87f580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2889194632a8, moduleTitle=康宁杰瑞与应世生物宣布合作开展，KN046联合IN10018的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2889194632a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040435, encodeId=4c0f2040435c7, content=<a href='/topic/show?id=0e5310542d9' target=_blank style='color:#2F92EE;'>#KN046#</a>, objectTitle=双特异性抗体KN026与KN046联合疗法获美国FDA孤儿药资格认定，用于治疗胃癌及胃食管连接部癌, objectType=article, longId=204839, objectId=18592048396e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18592048396e, replyNumber=0, likeNumber=77, createdTime=2021-11-21, rootId=0, userName=yilong5287542, userId=87f580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18592048396e, moduleTitle=双特异性抗体KN026与KN046联合疗法获美国FDA孤儿药资格认定，用于治疗胃癌及胃食管连接部癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18592048396e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

KN046

2020-05-29

梅斯管理员

#KN046# #KN026# #HER2阳性非乳腺癌#

STTT | KN026联合KN046在HER2阳性非乳腺癌中的疗效和安全性分析：一项Ib期和II期的综合分析

2025-03-22发表于陕西省

梅斯管理员

#三阴性乳腺癌# #白蛋白结合型紫杉醇# #KN046#

Nat. Commun：抗PD-L1/CTLA-4双特异性抗体KN046联合白蛋白结合型紫杉醇一线治疗转移性三阴性乳腺癌：多中心II期试验

2024-02-06发表于上海

yilong5287542

#KN046#

康宁杰瑞与应世生物宣布合作开展，KN046联合IN10018的临床研究

2021-03-01

yilong5287542

#KN046#

双特异性抗体KN026与KN046联合疗法获美国FDA孤儿药资格认定，用于治疗胃癌及胃食管连接部癌

2021-11-21

科室
- - 订阅+
  - 更多科室
工具
服务